Read original article at Astellas or PR Newswire
TOKYO and SAN FRANCISCO, Sept. 21, 2021 /PRNewswire/ — Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D, “AVM”), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), and Mission Bay Capital BioLabs (“MBC BioLabs”), a life-science incubator, today announced their third collaboration on the “Future Innovator Prize” formerly known as Astellas Golden Ticket. Building on the success of the inaugural competition held in 2019, the Golden Ticket Competition offers entrepreneurial scientists or emerging biotechnology start-ups one year’s priority usage of MBC BioLabs’ state-of-the-art lab facility and access to Astellas’ research and development (R&D) capabilities and business leaders.
With a shared commitment to discovering and advancing innovative science for the potential future benefit of patients worldwide, AVM and MBC BioLabs are continuing their partnership to support scientists and early-stage companies to accelerate their novel therapeutic programs, modalities or platforms.
“This is the third time we have worked with MBC BioLabs to identify emerging companies that can help us achieve and realize our VISION of turning innovative science into VALUE for patients,” said Maruyama, President, AVM. “The combination of Astellas’ R&D expertise and the capabilities of MBC BioLabs allow start-ups to transform exciting ideas into real businesses that could bring value and hope to patients around the world.”
“We are delighted to continue our partnership with Astellas,” said Douglas Crawford, MBC BioLabs General Manager. “The outstanding work of the previous winners of these Future Innovator Prize competitions is testament to what can be achieved by pairing Astellas’ ongoing support, advice and expertise with our laboratory accelerator. I’m very excited about what the next collaboration will bring.”
Entrepreneurial scientists, emerging life-science and biotechnology start-ups have until November 1, 2021 to enter the Golden Ticket Competition.
About the Future Innovator Prize at MBC BioLabs
Astellas is offering up to two Future Innovator Prizes for pioneering scientists with innovative research that complements Astellas’ areas of interest that fit with the Astellas Focus Area Approach and pipeline, including oncology, immunology, neuroscience including neuromuscular and sensory disorders.
Companies awarded an Astellas Future Innovator Prize will gain one year’s priority admission or renewal to MBC BioLabs’ state-of-the-art laboratory and access to Astellas’ R&D scientists and business leaders. The competition is open from September 21 to November 1, 2021. Entrepreneurial scientists, emerging life-science or biotechnology start-ups should submit their non-confidential company presentation, including a one-page executive summary, to https://astellasfutureinnovator.com/san-francisco.html to be considered. The decision to award any Golden Ticket and the assessments underlying such decision, are solely within the judgment of Astellas and MBC BioLabs and are not subject to any objection or appeal.
The 2020 Astellas Golden Ticket winners were Keyhole Therapeutics, Inc. and Jupiter Therapeutics, Inc., chosen for the potential of their innovations to deliver therapeutic advances for unmet medical needs and their potential synergy with Astellas’ Focus Area Approach.
For further information, please go to: http://www.astellasfutureinnovator.com/, where you can also find submission guidance for your non-confidential company presentation and executive summary.
About Astellas Venture Management LLC
AVM is the wholly-owned venture capital organization within Astellas, dedicated to supporting pre-clinical, cutting-edge science that can bring VALUE to patients. For over 15 years, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies, helping them to advance their innovations faster. AVM is a strategic investor, making investments in science that will enhance the current Astellas R&D pipeline or that could catalyze new directions in discovery research. For more information, please visit our website at https://www.astellasventure.com/.
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. Our strategy is based on a Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases of high unmet medical needs by focusing on the intersections of Biology with appropriate Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology from different fields. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.
About MBC BioLabs
MBC BioLabs is dedicated to helping life-science startups succeed. By renting space as small as a single bench and providing these entrepreneurial scientists with access to millions of dollars of equipment, we allow companies to be fast, focused, and frugal. We now have three sites: one in the Dogpatch neighborhood in San Francisco and two campuses in San Carlos. Each site has a complete molecular biology core facility that allows companies to do experiments on day one, not year one. We have partnerships with leading pharmaceutical and life-science companies as well as a built-in venture capital firm, Mission BioCapital. These partnerships provide our entrepreneurs with valuable insights about where to focus their efforts and accelerates the innovation pipeline. Our labs have truly enabled awesome: since our opening in 2013 we have helped launch and grow 230 companies. These companies have brought 54 programs to the clinic, produced 13 approved diagnostics, and raised over $7 billion!
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
SOURCE Astellas Pharma Inc.
For further information: Astellas Pharma Inc., Jarrod Aldom, Corporate Communications, +1 201-705-0254, email@example.com; MBC BioLabs, Flavia Nachbar, Public & Alliance Relations Coordinator, +1 415-347-8287, firstname.lastname@example.org or Linda Eng, Director of Operations, +1 415-347-8287, email@example.com